摘要
目的评价自体造血干细胞移植((AHSCT)治疗恶性血液病的临床疗效。方法回顾性分析42例行AHSCT的患者资料,其中标危病例为27例,高危病例为15例。结果除2例在造血重建过程中死亡外,余40例患者均获造血重建。该组患者3年和5年总生存率(OS)分别是(82.3±12.1)%和(77.2±9.6)%,3年和5年无病生存率(DFS)分别是(71.8±8.3)%和(69.2±9.2)%。标危与高危两组之间的5年OS分别为(96.1±4.1)%和(49.1±16.2)%,DFS分别为(92.1±4.2)%和(28.2±13.1)%,累积复发率分别为(19.1±8.2)%和(50.1±12.1)%,三者均有显著性意义(P<0.001)。AHSCT后维持治疗组的复发率较无维持治疗组显著降低(P<0.001)。结论AHSCT是治疗恶性血液病的有效手段,移植前患者的疾病状态是影响移植后复发的主要因素,移植后的维持治疗能有效地降低复发率。
Objective To evaluate the clinical efficacy of autologous hematopoietic stem cell transplantation （AHSCT） for hematological malignancies. Method 42 cases of performing AHSCT were analysed restrospectively, and 27 cases were standard risk patients, the other were high risk patients. Result Except 2 cases who died before re-establishing of haematogenesis, all patients were successfully engrafted. The 3 and 5 years of overall survival （OS） of these patients were （82.3 ± 2.1）% and （77.2 ± 9.6）%, and disease free survival （DFS） were （71.8 ± 8.3） % and （69.2 ± 9.2） % respectively.The 5 years of OS was （96.1 ± 4.1） % and （49.1 ± 16.2） %, DFS was （92.1 ± 4.2） % and （28.2 ± 13.1） %,cumulate relapse ratio was （19.1 ± 8.2） % and （50.1 ± 12.1） %,and they were evident difference in standard risk and high risk patients respectively （P〈0.001） .The cumulate relapse ratio were evident difference in the maintenance therapy and non-maintenance therapy post-AHSCT （P〈0.001）.Conclusion AHSCT is a good treatment for hematological malignancies. The morbid state before AHSCT was a main cause for relapse post-AHSCT, and the maintenance therapy post-AHSCT was effectively able to decrease relapse ratio.
出处
《中国血液流变学杂志》
CAS
2007年第4期565-567,共3页
Chinese Journal of Hemorheology
关键词
自体造血干细胞移植
恶性血液病
总生存率
无病生存率
Autologous hematopoietic stem cell transplantation
Hematological malignancies
Overall survival
Disease free survival
